Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 33 | 2018 | 388 | 5.520 |
Why?
|
Infectious Disease Transmission, Vertical | 19 | 2014 | 25 | 3.520 |
Why?
|
Pregnancy Complications, Infectious | 14 | 2013 | 32 | 2.800 |
Why?
|
Health Knowledge, Attitudes, Practice | 10 | 2022 | 353 | 2.790 |
Why?
|
Papillomavirus Infections | 5 | 2022 | 65 | 2.480 |
Why?
|
Humans | 145 | 2022 | 32297 | 2.110 |
Why?
|
Staphylococcal Infections | 6 | 2015 | 63 | 2.110 |
Why?
|
Sarcoidosis | 13 | 2012 | 27 | 2.070 |
Why?
|
India | 17 | 2020 | 65 | 2.070 |
Why?
|
Anti-Bacterial Agents | 17 | 2020 | 309 | 2.050 |
Why?
|
Papillomavirus Vaccines | 4 | 2022 | 44 | 2.020 |
Why?
|
Students, Medical | 3 | 2020 | 131 | 1.880 |
Why?
|
Child | 53 | 2018 | 2472 | 1.840 |
Why?
|
Female | 94 | 2022 | 20126 | 1.830 |
Why?
|
Breast Feeding | 14 | 2014 | 43 | 1.800 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 5 | 2015 | 29 | 1.740 |
Why?
|
Cross-Sectional Studies | 21 | 2022 | 1522 | 1.720 |
Why?
|
Patient Acceptance of Health Care | 4 | 2022 | 171 | 1.680 |
Why?
|
Anti-HIV Agents | 12 | 2014 | 54 | 1.640 |
Why?
|
Uterine Cervical Neoplasms | 4 | 2022 | 34 | 1.610 |
Why?
|
Infant | 39 | 2016 | 1076 | 1.580 |
Why?
|
Adolescent | 41 | 2021 | 3571 | 1.570 |
Why?
|
Male | 72 | 2021 | 19488 | 1.530 |
Why?
|
Child, Preschool | 31 | 2017 | 1281 | 1.410 |
Why?
|
Infant, Newborn | 22 | 2016 | 681 | 1.200 |
Why?
|
Adult | 37 | 2020 | 9467 | 1.130 |
Why?
|
Fever | 5 | 2015 | 63 | 1.130 |
Why?
|
Influenza, Human | 4 | 2012 | 124 | 1.030 |
Why?
|
HIV-1 | 10 | 2014 | 46 | 1.030 |
Why?
|
Condylomata Acuminata | 2 | 2022 | 7 | 0.990 |
Why?
|
Community-Acquired Infections | 5 | 2015 | 32 | 0.970 |
Why?
|
Depression, Postpartum | 4 | 2014 | 10 | 0.960 |
Why?
|
Pregnancy | 22 | 2014 | 1010 | 0.960 |
Why?
|
Diagnosis, Differential | 18 | 2015 | 525 | 0.940 |
Why?
|
Rural Population | 3 | 2020 | 274 | 0.930 |
Why?
|
Quality of Life | 4 | 2020 | 915 | 0.930 |
Why?
|
Papillomaviridae | 3 | 2018 | 20 | 0.900 |
Why?
|
Osteomyelitis | 3 | 2013 | 24 | 0.880 |
Why?
|
Influenza A Virus, H1N1 Subtype | 3 | 2012 | 49 | 0.870 |
Why?
|
Vaccination | 3 | 2022 | 137 | 0.860 |
Why?
|
Nevirapine | 6 | 2014 | 6 | 0.860 |
Why?
|
Zimbabwe | 19 | 2014 | 22 | 0.850 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2009 | 44 | 0.840 |
Why?
|
Antiviral Agents | 6 | 2012 | 110 | 0.840 |
Why?
|
Foster Home Care | 2 | 2017 | 3 | 0.830 |
Why?
|
Arthritis, Infectious | 3 | 2013 | 24 | 0.820 |
Why?
|
Health Services Accessibility | 4 | 2013 | 242 | 0.820 |
Why?
|
Immunocompromised Host | 3 | 2019 | 51 | 0.820 |
Why?
|
Women's Health | 3 | 2020 | 235 | 0.800 |
Why?
|
Epiglottitis | 1 | 2021 | 2 | 0.780 |
Why?
|
Milk, Human | 6 | 2013 | 16 | 0.780 |
Why?
|
Pediatrics | 3 | 2021 | 158 | 0.780 |
Why?
|
Microcephaly | 2 | 2017 | 3 | 0.780 |
Why?
|
Tomography, X-Ray Computed | 10 | 2021 | 920 | 0.760 |
Why?
|
Marijuana Smoking | 1 | 2021 | 39 | 0.750 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 3 | 2009 | 9 | 0.750 |
Why?
|
Mass Screening | 3 | 2009 | 263 | 0.740 |
Why?
|
Biofuels | 1 | 2020 | 1 | 0.730 |
Why?
|
Hepatitis B, Chronic | 1 | 2020 | 7 | 0.730 |
Why?
|
Air Pollution, Indoor | 1 | 2020 | 8 | 0.730 |
Why?
|
Self Disclosure | 1 | 2020 | 23 | 0.720 |
Why?
|
Vincristine | 2 | 2019 | 18 | 0.720 |
Why?
|
Drug Prescriptions | 1 | 2020 | 54 | 0.710 |
Why?
|
Sepsis | 2 | 2015 | 156 | 0.690 |
Why?
|
Attitude of Health Personnel | 2 | 2020 | 182 | 0.680 |
Why?
|
Middle Aged | 16 | 2020 | 11949 | 0.680 |
Why?
|
Students, Dental | 1 | 2019 | 2 | 0.670 |
Why?
|
Sarcoma, Kaposi | 1 | 2019 | 8 | 0.670 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2019 | 6 | 0.670 |
Why?
|
Pneumocystis carinii | 1 | 2019 | 6 | 0.670 |
Why?
|
Students, Nursing | 1 | 2019 | 7 | 0.670 |
Why?
|
Hemangioendothelioma | 1 | 2019 | 10 | 0.670 |
Why?
|
Drug Resistance, Bacterial | 3 | 2020 | 42 | 0.670 |
Why?
|
Burns | 2 | 2021 | 102 | 0.670 |
Why?
|
Sirolimus | 1 | 2019 | 34 | 0.670 |
Why?
|
Delayed Diagnosis | 1 | 2018 | 16 | 0.650 |
Why?
|
Anti-Retroviral Agents | 1 | 2018 | 21 | 0.650 |
Why?
|
Anxiety | 1 | 2020 | 185 | 0.640 |
Why?
|
Young Adult | 15 | 2020 | 2626 | 0.630 |
Why?
|
Health Status | 2 | 2020 | 402 | 0.620 |
Why?
|
Prenatal Care | 3 | 2007 | 52 | 0.610 |
Why?
|
Bacteremia | 3 | 2013 | 58 | 0.610 |
Why?
|
Early Detection of Cancer | 2 | 2016 | 87 | 0.600 |
Why?
|
Echinococcus | 1 | 2017 | 1 | 0.600 |
Why?
|
Echinococcosis | 1 | 2017 | 2 | 0.600 |
Why?
|
Disease Outbreaks | 1 | 2017 | 38 | 0.580 |
Why?
|
Exanthema | 3 | 2013 | 21 | 0.580 |
Why?
|
Abscess | 3 | 2015 | 26 | 0.580 |
Why?
|
Cervical Intraepithelial Neoplasia | 1 | 2016 | 2 | 0.570 |
Why?
|
Spleen | 1 | 2017 | 87 | 0.570 |
Why?
|
Streptococcus pyogenes | 2 | 2010 | 16 | 0.570 |
Why?
|
Ciprofloxacin | 2 | 2015 | 12 | 0.560 |
Why?
|
Depression | 1 | 2020 | 436 | 0.560 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 154 | 0.560 |
Why?
|
Maternal-Child Health Centers | 2 | 2013 | 4 | 0.560 |
Why?
|
Head and Neck Neoplasms | 1 | 2018 | 129 | 0.560 |
Why?
|
Urinary Tract Infections | 2 | 2015 | 50 | 0.550 |
Why?
|
Public Health | 1 | 2017 | 83 | 0.550 |
Why?
|
Urban Population | 3 | 2020 | 87 | 0.550 |
Why?
|
Child Welfare | 1 | 2016 | 21 | 0.540 |
Why?
|
Chromobacterium | 1 | 2015 | 1 | 0.530 |
Why?
|
Imipenem | 1 | 2015 | 1 | 0.530 |
Why?
|
Shock, Septic | 1 | 2015 | 26 | 0.530 |
Why?
|
CD4 Lymphocyte Count | 6 | 2018 | 32 | 0.520 |
Why?
|
Abdominal Abscess | 1 | 2015 | 6 | 0.520 |
Why?
|
Frontal Sinusitis | 1 | 2015 | 5 | 0.520 |
Why?
|
Epidural Abscess | 1 | 2015 | 5 | 0.520 |
Why?
|
Follow-Up Studies | 8 | 2019 | 2296 | 0.520 |
Why?
|
Guanidines | 2 | 2012 | 6 | 0.510 |
Why?
|
Patient Compliance | 1 | 2017 | 227 | 0.510 |
Why?
|
Cyclopentanes | 2 | 2012 | 17 | 0.510 |
Why?
|
Physicians | 1 | 2017 | 161 | 0.500 |
Why?
|
Escherichia coli Infections | 1 | 2015 | 40 | 0.500 |
Why?
|
Invasive Pulmonary Aspergillosis | 1 | 2014 | 2 | 0.490 |
Why?
|
Pneumonia, Viral | 2 | 2011 | 118 | 0.480 |
Why?
|
Cough | 1 | 2014 | 20 | 0.480 |
Why?
|
Retinitis | 2 | 2005 | 3 | 0.480 |
Why?
|
Methotrexate | 4 | 2015 | 64 | 0.480 |
Why?
|
Travel | 3 | 2009 | 15 | 0.460 |
Why?
|
Counseling | 4 | 2007 | 99 | 0.460 |
Why?
|
Edema | 2 | 2015 | 30 | 0.460 |
Why?
|
Attitude to Health | 2 | 2015 | 167 | 0.460 |
Why?
|
Diabetes Mellitus | 1 | 2017 | 410 | 0.450 |
Why?
|
Drug Resistance, Viral | 2 | 2011 | 10 | 0.450 |
Why?
|
Glucose Oxidase | 1 | 2013 | 1 | 0.450 |
Why?
|
Lactoperoxidase | 1 | 2013 | 1 | 0.450 |
Why?
|
Pneumonia, Ventilator-Associated | 1 | 2013 | 8 | 0.450 |
Why?
|
Muramidase | 1 | 2013 | 8 | 0.450 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2003 | 17 | 0.450 |
Why?
|
Oral Hygiene | 1 | 2013 | 16 | 0.450 |
Why?
|
Rocky Mountain Spotted Fever | 1 | 2013 | 8 | 0.440 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 9 | 0.440 |
Why?
|
Intracranial Hypertension | 1 | 2013 | 21 | 0.440 |
Why?
|
Parotitis | 1 | 2012 | 2 | 0.440 |
Why?
|
Conjunctivitis | 1 | 2012 | 3 | 0.430 |
Why?
|
Mycoplasma pneumoniae | 1 | 2012 | 5 | 0.430 |
Why?
|
Pneumonia, Mycoplasma | 1 | 2012 | 4 | 0.430 |
Why?
|
Fatal Outcome | 7 | 2018 | 86 | 0.430 |
Why?
|
Mucositis | 1 | 2012 | 8 | 0.430 |
Why?
|
Drug Therapy, Combination | 5 | 2019 | 301 | 0.430 |
Why?
|
Preventive Health Services | 1 | 2013 | 44 | 0.430 |
Why?
|
Socioeconomic Factors | 7 | 2020 | 422 | 0.420 |
Why?
|
Streptococcal Infections | 2 | 2010 | 22 | 0.420 |
Why?
|
Kidney Diseases | 1 | 2015 | 255 | 0.420 |
Why?
|
Neuraminidase | 1 | 2012 | 10 | 0.410 |
Why?
|
Viral Proteins | 1 | 2012 | 42 | 0.400 |
Why?
|
Arthritis | 3 | 2015 | 40 | 0.400 |
Why?
|
Diarrhea, Infantile | 2 | 2009 | 5 | 0.400 |
Why?
|
Purpura Fulminans | 1 | 2011 | 4 | 0.400 |
Why?
|
Viral Load | 5 | 2013 | 70 | 0.390 |
Why?
|
Orbital Cellulitis | 1 | 2011 | 1 | 0.390 |
Why?
|
Intention | 2 | 2022 | 28 | 0.390 |
Why?
|
Eye Infections, Bacterial | 1 | 2011 | 5 | 0.390 |
Why?
|
Risk Factors | 9 | 2018 | 3876 | 0.390 |
Why?
|
Oseltamivir | 1 | 2011 | 6 | 0.390 |
Why?
|
Vasculitis | 3 | 2003 | 23 | 0.380 |
Why?
|
Developing Countries | 4 | 2013 | 46 | 0.380 |
Why?
|
World Health Organization | 3 | 2017 | 15 | 0.370 |
Why?
|
Prognosis | 7 | 2018 | 1523 | 0.370 |
Why?
|
Pharyngitis | 1 | 2010 | 10 | 0.360 |
Why?
|
Mastitis | 4 | 2013 | 4 | 0.360 |
Why?
|
Risk Assessment | 6 | 2019 | 1447 | 0.360 |
Why?
|
Jugular Veins | 1 | 2010 | 26 | 0.360 |
Why?
|
Dengue | 1 | 2009 | 5 | 0.350 |
Why?
|
Venous Thrombosis | 1 | 2010 | 50 | 0.350 |
Why?
|
Interview, Psychological | 1 | 2009 | 10 | 0.350 |
Why?
|
Mothers | 4 | 2013 | 87 | 0.350 |
Why?
|
Pyomyositis | 1 | 2009 | 2 | 0.340 |
Why?
|
Entamoebiasis | 1 | 2009 | 1 | 0.340 |
Why?
|
Liver Abscess | 1 | 2009 | 2 | 0.340 |
Why?
|
Anemia, Aplastic | 1 | 2009 | 5 | 0.340 |
Why?
|
Odds Ratio | 3 | 2020 | 480 | 0.340 |
Why?
|
Platelet Transfusion | 1 | 2009 | 16 | 0.340 |
Why?
|
Gram-Negative Bacterial Infections | 2 | 2006 | 14 | 0.340 |
Why?
|
Streptococcus pneumoniae | 1 | 2009 | 39 | 0.330 |
Why?
|
Treatment Outcome | 11 | 2015 | 3358 | 0.330 |
Why?
|
Pharyngeal Diseases | 1 | 2009 | 9 | 0.330 |
Why?
|
Abdominal Pain | 1 | 2009 | 45 | 0.330 |
Why?
|
Acute Lung Injury | 1 | 2009 | 32 | 0.330 |
Why?
|
Antirheumatic Agents | 2 | 1999 | 30 | 0.320 |
Why?
|
Pneumonia | 2 | 1999 | 67 | 0.320 |
Why?
|
Herpes Simplex | 1 | 2008 | 14 | 0.320 |
Why?
|
Liver Failure, Acute | 1 | 2008 | 10 | 0.320 |
Why?
|
Ustilaginales | 1 | 2008 | 3 | 0.320 |
Why?
|
Fungemia | 1 | 2008 | 3 | 0.320 |
Why?
|
Short Bowel Syndrome | 1 | 2008 | 12 | 0.310 |
Why?
|
Anemia, Sickle Cell | 2 | 1998 | 43 | 0.310 |
Why?
|
Lupus Erythematosus, Systemic | 3 | 2000 | 148 | 0.310 |
Why?
|
Microbial Sensitivity Tests | 4 | 2015 | 64 | 0.310 |
Why?
|
Sinusitis | 2 | 2006 | 19 | 0.300 |
Why?
|
Catheterization, Central Venous | 1 | 2008 | 63 | 0.300 |
Why?
|
Retrospective Studies | 8 | 2018 | 3514 | 0.290 |
Why?
|
Malaria | 1 | 2006 | 11 | 0.290 |
Why?
|
Malaria, Falciparum | 2 | 1999 | 3 | 0.290 |
Why?
|
AIDS Serodiagnosis | 2 | 2006 | 4 | 0.290 |
Why?
|
Orbital Diseases | 1 | 2006 | 7 | 0.280 |
Why?
|
Cellulitis | 1 | 2006 | 11 | 0.280 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2006 | 23 | 0.280 |
Why?
|
Methylobacteriaceae | 1 | 2006 | 2 | 0.280 |
Why?
|
Anti-Inflammatory Agents | 4 | 2009 | 102 | 0.270 |
Why?
|
Neuroblastoma | 1 | 2006 | 33 | 0.270 |
Why?
|
Catheterization | 1 | 2006 | 59 | 0.270 |
Why?
|
Leukemia, T-Cell | 1 | 2005 | 2 | 0.260 |
Why?
|
Cohort Studies | 4 | 2019 | 1832 | 0.260 |
Why?
|
Chickenpox | 1 | 2005 | 4 | 0.260 |
Why?
|
Postoperative Complications | 1 | 2011 | 788 | 0.260 |
Why?
|
Glucocorticoids | 2 | 2004 | 161 | 0.260 |
Why?
|
Meningoencephalitis | 2 | 2002 | 4 | 0.260 |
Why?
|
Time Factors | 6 | 2018 | 2181 | 0.250 |
Why?
|
Probiotics | 1 | 2005 | 10 | 0.250 |
Why?
|
Lactobacillus | 1 | 2005 | 14 | 0.250 |
Why?
|
Africa South of the Sahara | 3 | 2013 | 21 | 0.250 |
Why?
|
Mental Disorders | 1 | 2005 | 119 | 0.240 |
Why?
|
Psychotherapy, Group | 2 | 2014 | 17 | 0.240 |
Why?
|
Cavernous Sinus Thrombosis | 1 | 2004 | 2 | 0.240 |
Why?
|
Age Factors | 4 | 2018 | 1204 | 0.230 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 2003 | 2 | 0.230 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2003 | 6 | 0.230 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2003 | 10 | 0.230 |
Why?
|
Meningitis, Viral | 1 | 2003 | 1 | 0.230 |
Why?
|
Enterovirus B, Human | 1 | 2003 | 1 | 0.230 |
Why?
|
Coxsackievirus Infections | 1 | 2003 | 2 | 0.230 |
Why?
|
Encephalitis, Viral | 1 | 2003 | 4 | 0.230 |
Why?
|
Cerebral Ventricles | 1 | 2003 | 11 | 0.230 |
Why?
|
Bacterial Infections | 2 | 2001 | 52 | 0.230 |
Why?
|
Post-Exposure Prophylaxis | 2 | 2013 | 4 | 0.220 |
Why?
|
Primary Prevention | 1 | 2003 | 54 | 0.220 |
Why?
|
DNA, Viral | 4 | 2018 | 52 | 0.220 |
Why?
|
Poliovirus Vaccine, Oral | 2 | 2013 | 3 | 0.220 |
Why?
|
Mumps | 1 | 2002 | 2 | 0.220 |
Why?
|
Animals | 6 | 2017 | 7694 | 0.220 |
Why?
|
Angiolymphoid Hyperplasia with Eosinophilia | 1 | 2002 | 3 | 0.220 |
Why?
|
Lymphadenitis | 2 | 2015 | 3 | 0.210 |
Why?
|
Severity of Illness Index | 4 | 2014 | 926 | 0.210 |
Why?
|
Penicillins | 2 | 2001 | 9 | 0.210 |
Why?
|
Meningitis, Bacterial | 1 | 2001 | 4 | 0.200 |
Why?
|
Crohn Disease | 2 | 1999 | 26 | 0.200 |
Why?
|
Drug Administration Schedule | 4 | 2013 | 279 | 0.200 |
Why?
|
Immunoglobulins, Intravenous | 3 | 2009 | 24 | 0.200 |
Why?
|
Medication Adherence | 1 | 2013 | 161 | 0.200 |
Why?
|
Bacteriological Techniques | 1 | 2001 | 15 | 0.190 |
Why?
|
Laryngoscopy | 1 | 2021 | 41 | 0.190 |
Why?
|
Costa Rica | 1 | 2020 | 1 | 0.190 |
Why?
|
Suburban Population | 1 | 2020 | 5 | 0.190 |
Why?
|
Deglutition Disorders | 1 | 2021 | 50 | 0.190 |
Why?
|
Viral Vaccines | 1 | 2020 | 13 | 0.190 |
Why?
|
Nephrotic Syndrome | 2 | 1999 | 13 | 0.190 |
Why?
|
Disease Progression | 2 | 2018 | 618 | 0.190 |
Why?
|
Purpura, Schoenlein-Henoch | 1 | 2000 | 4 | 0.180 |
Why?
|
Clindamycin | 2 | 2011 | 21 | 0.180 |
Why?
|
Lymphocytes | 2 | 2014 | 58 | 0.180 |
Why?
|
China | 1 | 2020 | 50 | 0.180 |
Why?
|
Postpartum Period | 2 | 2014 | 34 | 0.180 |
Why?
|
Rett Syndrome | 1 | 2000 | 1 | 0.180 |
Why?
|
Virus Shedding | 2 | 2013 | 5 | 0.180 |
Why?
|
Sexual Partners | 1 | 2020 | 35 | 0.180 |
Why?
|
Tracheoesophageal Fistula | 1 | 2000 | 5 | 0.180 |
Why?
|
Adenovirus Infections, Human | 1 | 2000 | 5 | 0.180 |
Why?
|
Lipid Metabolism, Inborn Errors | 1 | 1999 | 2 | 0.180 |
Why?
|
Acyl-CoA Dehydrogenases | 1 | 1999 | 2 | 0.180 |
Why?
|
Ribavirin | 1 | 2000 | 28 | 0.180 |
Why?
|
Nocardia Infections | 1 | 1999 | 2 | 0.180 |
Why?
|
Enterobacteriaceae | 1 | 2019 | 9 | 0.180 |
Why?
|
Fibrosarcoma | 1 | 1999 | 4 | 0.180 |
Why?
|
Granulomatous Disease, Chronic | 1 | 1999 | 6 | 0.180 |
Why?
|
Toxocariasis | 1 | 1999 | 1 | 0.180 |
Why?
|
Toxocara canis | 1 | 1999 | 1 | 0.180 |
Why?
|
Hepatitis | 1 | 1999 | 8 | 0.180 |
Why?
|
Neutrophils | 2 | 2013 | 118 | 0.170 |
Why?
|
Encephalocele | 1 | 1999 | 2 | 0.170 |
Why?
|
Typhoid Fever | 1 | 1999 | 20 | 0.170 |
Why?
|
Chronic Disease | 2 | 2014 | 406 | 0.170 |
Why?
|
Iritis | 1 | 1999 | 1 | 0.170 |
Why?
|
Pilot Projects | 3 | 2013 | 536 | 0.170 |
Why?
|
Injections, Intravenous | 3 | 2009 | 79 | 0.170 |
Why?
|
Environmental Exposure | 1 | 2020 | 92 | 0.170 |
Why?
|
Methylprednisolone | 2 | 1999 | 13 | 0.170 |
Why?
|
Sensitivity and Specificity | 3 | 2009 | 600 | 0.170 |
Why?
|
Spinal Puncture | 1 | 1999 | 21 | 0.170 |
Why?
|
Logistic Models | 3 | 2018 | 788 | 0.170 |
Why?
|
Fatty Acids | 1 | 1999 | 97 | 0.170 |
Why?
|
Nutritional Status | 1 | 1999 | 73 | 0.170 |
Why?
|
Liver Diseases | 1 | 1999 | 70 | 0.170 |
Why?
|
Rickets | 1 | 1998 | 3 | 0.170 |
Why?
|
Antacids | 1 | 1998 | 4 | 0.170 |
Why?
|
Internet | 1 | 2020 | 203 | 0.170 |
Why?
|
Tuberculosis | 2 | 2014 | 15 | 0.170 |
Why?
|
Linear Models | 1 | 2020 | 454 | 0.170 |
Why?
|
Hypophosphatemia | 1 | 1998 | 6 | 0.160 |
Why?
|
Prednisone | 2 | 2015 | 62 | 0.160 |
Why?
|
Blastomycosis | 1 | 1998 | 2 | 0.160 |
Why?
|
Hemoptysis | 1 | 1998 | 3 | 0.160 |
Why?
|
Child Abuse, Sexual | 1 | 1998 | 6 | 0.160 |
Why?
|
Bronchoalveolar Lavage Fluid | 2 | 2014 | 77 | 0.160 |
Why?
|
Clostridium Infections | 1 | 1998 | 10 | 0.160 |
Why?
|
Antisickling Agents | 1 | 1998 | 1 | 0.160 |
Why?
|
Quinine | 2 | 1999 | 3 | 0.160 |
Why?
|
Hydroxyurea | 1 | 1998 | 3 | 0.160 |
Why?
|
Thoracic Diseases | 1 | 1998 | 4 | 0.160 |
Why?
|
Urethral Diseases | 1 | 1998 | 18 | 0.160 |
Why?
|
Hamartoma | 1 | 1998 | 10 | 0.160 |
Why?
|
Professional Practice | 1 | 1998 | 24 | 0.160 |
Why?
|
Prospective Studies | 5 | 2018 | 2274 | 0.160 |
Why?
|
Lymphatic Diseases | 1 | 1998 | 10 | 0.160 |
Why?
|
Takayasu Arteritis | 1 | 1998 | 1 | 0.160 |
Why?
|
Africa | 4 | 2014 | 27 | 0.160 |
Why?
|
Vascular Diseases | 1 | 1999 | 66 | 0.160 |
Why?
|
Airway Obstruction | 1 | 1998 | 32 | 0.160 |
Why?
|
Emergencies | 1 | 1998 | 47 | 0.160 |
Why?
|
Louisiana | 4 | 2015 | 11 | 0.160 |
Why?
|
Scurvy | 1 | 1998 | 3 | 0.160 |
Why?
|
Craniosynostoses | 1 | 1998 | 62 | 0.160 |
Why?
|
Death, Sudden, Cardiac | 1 | 2018 | 63 | 0.150 |
Why?
|
Ribs | 1 | 1998 | 44 | 0.150 |
Why?
|
Helicobacter pylori | 1 | 1997 | 6 | 0.150 |
Why?
|
Gastritis | 1 | 1997 | 4 | 0.150 |
Why?
|
Helicobacter Infections | 1 | 1997 | 8 | 0.150 |
Why?
|
Dermatitis | 1 | 1997 | 21 | 0.150 |
Why?
|
Insect Vectors | 1 | 2017 | 3 | 0.150 |
Why?
|
Vancomycin | 2 | 2011 | 20 | 0.150 |
Why?
|
Age Distribution | 2 | 2013 | 210 | 0.150 |
Why?
|
Guillain-Barre Syndrome | 1 | 2017 | 8 | 0.150 |
Why?
|
Pruritus | 1 | 2018 | 64 | 0.150 |
Why?
|
Splenectomy | 1 | 2017 | 21 | 0.150 |
Why?
|
Prion Diseases | 1 | 1997 | 3 | 0.150 |
Why?
|
Familial Mediterranean Fever | 1 | 1996 | 2 | 0.140 |
Why?
|
Human papillomavirus 18 | 1 | 2016 | 1 | 0.140 |
Why?
|
Human papillomavirus 16 | 1 | 2016 | 3 | 0.140 |
Why?
|
Aged | 4 | 2018 | 10398 | 0.140 |
Why?
|
Magnetic Resonance Imaging | 4 | 2017 | 1345 | 0.140 |
Why?
|
Prevalence | 3 | 2018 | 986 | 0.140 |
Why?
|
Antibodies, Viral | 3 | 2013 | 60 | 0.140 |
Why?
|
Child Mortality | 1 | 2016 | 2 | 0.140 |
Why?
|
Maternal Mortality | 1 | 2016 | 12 | 0.140 |
Why?
|
Drug Administration Routes | 2 | 2012 | 12 | 0.130 |
Why?
|
Health Personnel | 1 | 2017 | 121 | 0.130 |
Why?
|
Melioidosis | 1 | 2015 | 2 | 0.130 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 1999 | 462 | 0.130 |
Why?
|
Infant Mortality | 1 | 2016 | 23 | 0.130 |
Why?
|
Feasibility Studies | 2 | 2014 | 294 | 0.130 |
Why?
|
Physician's Role | 1 | 2016 | 41 | 0.130 |
Why?
|
beta-Lactamases | 1 | 2015 | 8 | 0.130 |
Why?
|
Immunoglobulin G | 2 | 2013 | 121 | 0.130 |
Why?
|
Skin | 1 | 1997 | 217 | 0.130 |
Why?
|
Forehead | 1 | 2015 | 13 | 0.130 |
Why?
|
Clinical Competence | 1 | 1998 | 331 | 0.130 |
Why?
|
Uveitis | 1 | 2015 | 2 | 0.130 |
Why?
|
Synovitis | 1 | 2015 | 6 | 0.130 |
Why?
|
Escherichia coli | 1 | 2015 | 87 | 0.130 |
Why?
|
Genotype | 1 | 2016 | 742 | 0.120 |
Why?
|
Problem Solving | 1 | 2014 | 28 | 0.120 |
Why?
|
Perception | 1 | 2015 | 98 | 0.120 |
Why?
|
Chemoprevention | 1 | 2014 | 10 | 0.120 |
Why?
|
Urban Health | 2 | 2011 | 14 | 0.120 |
Why?
|
Social Support | 2 | 2007 | 180 | 0.120 |
Why?
|
South Africa | 2 | 2013 | 11 | 0.120 |
Why?
|
Meningitis, Meningococcal | 1 | 2013 | 1 | 0.120 |
Why?
|
Meningococcal Infections | 1 | 2013 | 6 | 0.120 |
Why?
|
Healthcare Disparities | 1 | 2016 | 166 | 0.110 |
Why?
|
Poliovirus | 1 | 2013 | 3 | 0.110 |
Why?
|
North Carolina | 2 | 2009 | 1520 | 0.110 |
Why?
|
Monocytes | 1 | 2014 | 126 | 0.110 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2013 | 1 | 0.110 |
Why?
|
Rickettsia rickettsii | 1 | 2013 | 3 | 0.110 |
Why?
|
Palatine Tonsil | 1 | 2013 | 6 | 0.110 |
Why?
|
Directive Counseling | 1 | 2013 | 18 | 0.110 |
Why?
|
Length of Stay | 2 | 2013 | 315 | 0.110 |
Why?
|
Drug Combinations | 1 | 2013 | 93 | 0.110 |
Why?
|
Mouth Mucosa | 1 | 2013 | 31 | 0.110 |
Why?
|
Parotid Gland | 1 | 2012 | 6 | 0.110 |
Why?
|
Azithromycin | 1 | 2012 | 15 | 0.110 |
Why?
|
Administration, Topical | 1 | 2013 | 140 | 0.110 |
Why?
|
Biopsy | 3 | 1998 | 273 | 0.110 |
Why?
|
Intestinal Mucosa | 1 | 2013 | 71 | 0.110 |
Why?
|
Sex Distribution | 1 | 2013 | 201 | 0.110 |
Why?
|
Respiration, Artificial | 1 | 2013 | 100 | 0.110 |
Why?
|
Vaginal Discharge | 1 | 2012 | 3 | 0.100 |
Why?
|
Lung | 1 | 2014 | 262 | 0.100 |
Why?
|
Shigella flexneri | 1 | 2012 | 3 | 0.100 |
Why?
|
Vaginosis, Bacterial | 1 | 2012 | 7 | 0.100 |
Why?
|
Cost-Benefit Analysis | 1 | 2013 | 187 | 0.100 |
Why?
|
Dysentery, Bacillary | 1 | 2012 | 12 | 0.100 |
Why?
|
Poliomyelitis | 1 | 2012 | 4 | 0.100 |
Why?
|
Syndrome | 2 | 2010 | 74 | 0.100 |
Why?
|
Drug Dosage Calculations | 1 | 2012 | 8 | 0.100 |
Why?
|
Ferrets | 1 | 2012 | 20 | 0.100 |
Why?
|
Neutropenia | 1 | 2012 | 30 | 0.100 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2012 | 28 | 0.100 |
Why?
|
Molecular Structure | 1 | 2012 | 60 | 0.100 |
Why?
|
HIV Seropositivity | 1 | 2012 | 14 | 0.100 |
Why?
|
Multivariate Analysis | 2 | 2011 | 696 | 0.100 |
Why?
|
Double-Blind Method | 3 | 2014 | 550 | 0.100 |
Why?
|
Drug Design | 1 | 2012 | 47 | 0.100 |
Why?
|
Brain | 1 | 1999 | 971 | 0.100 |
Why?
|
RNA, Viral | 5 | 2013 | 52 | 0.100 |
Why?
|
Anemia | 1 | 2012 | 60 | 0.100 |
Why?
|
Safety | 2 | 2003 | 78 | 0.100 |
Why?
|
Immunologic Tests | 1 | 2011 | 6 | 0.100 |
Why?
|
Gravidity | 1 | 2011 | 3 | 0.100 |
Why?
|
Hematologic Tests | 1 | 2011 | 11 | 0.100 |
Why?
|
Endemic Diseases | 2 | 2011 | 4 | 0.100 |
Why?
|
Drugs, Investigational | 1 | 2011 | 7 | 0.100 |
Why?
|
Central Nervous System | 2 | 2004 | 46 | 0.100 |
Why?
|
Drainage | 1 | 2011 | 72 | 0.090 |
Why?
|
Parity | 1 | 2010 | 20 | 0.090 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 27 | 0.090 |
Why?
|
Genes, env | 1 | 2010 | 1 | 0.090 |
Why?
|
Patient Education as Topic | 1 | 2013 | 276 | 0.090 |
Why?
|
Doxycycline | 2 | 2002 | 25 | 0.090 |
Why?
|
Statistics, Nonparametric | 2 | 2011 | 133 | 0.090 |
Why?
|
Monitoring, Physiologic | 1 | 2011 | 77 | 0.090 |
Why?
|
Ceftriaxone | 2 | 2001 | 12 | 0.090 |
Why?
|
Chi-Square Distribution | 2 | 2011 | 302 | 0.090 |
Why?
|
Dengue Virus | 1 | 2009 | 4 | 0.090 |
Why?
|
Guatemala | 1 | 2009 | 10 | 0.090 |
Why?
|
Cytomegalovirus Infections | 2 | 2008 | 47 | 0.090 |
Why?
|
Interviews as Topic | 1 | 2010 | 263 | 0.090 |
Why?
|
Cyclophosphamide | 3 | 2015 | 37 | 0.090 |
Why?
|
Uganda | 2 | 2013 | 8 | 0.080 |
Why?
|
Opportunistic Infections | 1 | 2009 | 17 | 0.080 |
Why?
|
Prednisolone | 2 | 1999 | 11 | 0.080 |
Why?
|
Causality | 2 | 2015 | 39 | 0.080 |
Why?
|
Ambulatory Care Facilities | 2 | 2006 | 83 | 0.080 |
Why?
|
Simplexvirus | 1 | 2008 | 3 | 0.080 |
Why?
|
Liver Transplantation | 2 | 2000 | 179 | 0.080 |
Why?
|
Aspirin | 1 | 2009 | 65 | 0.080 |
Why?
|
Immunologic Factors | 1 | 2009 | 49 | 0.080 |
Why?
|
Mycoses | 1 | 2008 | 21 | 0.080 |
Why?
|
Adrenal Cortex Hormones | 2 | 2000 | 163 | 0.080 |
Why?
|
Comorbidity | 1 | 2009 | 572 | 0.080 |
Why?
|
Bone Marrow | 2 | 2006 | 71 | 0.080 |
Why?
|
Mental Health Services | 1 | 2007 | 28 | 0.070 |
Why?
|
Emergency Service, Hospital | 1 | 2011 | 463 | 0.070 |
Why?
|
Disease Transmission, Infectious | 1 | 2007 | 17 | 0.070 |
Why?
|
Reproducibility of Results | 1 | 2009 | 779 | 0.070 |
Why?
|
Radiography | 2 | 1998 | 377 | 0.070 |
Why?
|
Prenatal Diagnosis | 1 | 2006 | 27 | 0.070 |
Why?
|
Lymphocyte Count | 1 | 2006 | 25 | 0.070 |
Why?
|
Diagnostic Imaging | 1 | 2007 | 93 | 0.070 |
Why?
|
Drug Monitoring | 1 | 2006 | 26 | 0.070 |
Why?
|
Heart Arrest | 1 | 2006 | 37 | 0.070 |
Why?
|
Skin Ulcer | 1 | 2006 | 11 | 0.070 |
Why?
|
Remission Induction | 1 | 2006 | 84 | 0.070 |
Why?
|
Species Specificity | 1 | 2006 | 90 | 0.070 |
Why?
|
Kidney Transplantation | 1 | 2011 | 518 | 0.070 |
Why?
|
Seroepidemiologic Studies | 1 | 2005 | 10 | 0.070 |
Why?
|
Diet | 2 | 1999 | 384 | 0.070 |
Why?
|
Red Cross | 1 | 2005 | 2 | 0.070 |
Why?
|
Incidence | 2 | 2000 | 1207 | 0.070 |
Why?
|
Pregnancy Trimester, Third | 1 | 2005 | 18 | 0.070 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2005 | 7 | 0.070 |
Why?
|
Pleural Effusion | 1 | 2005 | 13 | 0.070 |
Why?
|
Chickenpox Vaccine | 1 | 2005 | 3 | 0.070 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2005 | 99 | 0.070 |
Why?
|
Acyclovir | 1 | 2005 | 13 | 0.070 |
Why?
|
Mice | 1 | 2012 | 2524 | 0.070 |
Why?
|
Cost of Illness | 1 | 2005 | 70 | 0.070 |
Why?
|
Administration, Oral | 2 | 2011 | 185 | 0.060 |
Why?
|
Immunosuppressive Agents | 2 | 2004 | 238 | 0.060 |
Why?
|
DNA Fingerprinting | 1 | 2005 | 7 | 0.060 |
Why?
|
Bacterial Typing Techniques | 1 | 2005 | 10 | 0.060 |
Why?
|
Mononuclear Phagocyte System | 1 | 2004 | 2 | 0.060 |
Why?
|
Immune System | 1 | 2004 | 8 | 0.060 |
Why?
|
Immunity, Cellular | 1 | 2004 | 22 | 0.060 |
Why?
|
Gastrointestinal Tract | 1 | 2004 | 29 | 0.060 |
Why?
|
Hemorrhage | 1 | 2005 | 101 | 0.060 |
Why?
|
Musculoskeletal System | 1 | 2004 | 13 | 0.060 |
Why?
|
Bone Diseases, Metabolic | 1 | 2004 | 21 | 0.060 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2004 | 12 | 0.060 |
Why?
|
Diarrhea | 1 | 2005 | 60 | 0.060 |
Why?
|
Combined Modality Therapy | 1 | 2006 | 567 | 0.060 |
Why?
|
Amitriptyline | 2 | 2014 | 7 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2005 | 140 | 0.060 |
Why?
|
Leukocyte Count | 2 | 2014 | 64 | 0.060 |
Why?
|
Bottle Feeding | 1 | 2004 | 1 | 0.060 |
Why?
|
Viridans Streptococci | 1 | 2004 | 4 | 0.060 |
Why?
|
Blindness | 1 | 2004 | 10 | 0.060 |
Why?
|
Epidemiologic Research Design | 1 | 2003 | 5 | 0.060 |
Why?
|
Metabolic Clearance Rate | 1 | 2003 | 19 | 0.060 |
Why?
|
Maternal Age | 1 | 2003 | 15 | 0.060 |
Why?
|
Tanzania | 1 | 2013 | 12 | 0.060 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2004 | 26 | 0.060 |
Why?
|
Methane | 1 | 2003 | 1 | 0.060 |
Why?
|
Hydrogen | 1 | 2003 | 8 | 0.060 |
Why?
|
Colic | 1 | 2003 | 3 | 0.060 |
Why?
|
Colony Count, Microbial | 1 | 2003 | 18 | 0.060 |
Why?
|
Culture Media | 1 | 2003 | 45 | 0.060 |
Why?
|
Respiratory Distress Syndrome, Adult | 1 | 2004 | 55 | 0.060 |
Why?
|
United States | 3 | 2011 | 3983 | 0.060 |
Why?
|
Clinical Laboratory Techniques | 1 | 2003 | 25 | 0.060 |
Why?
|
Communicable Disease Control | 1 | 2003 | 15 | 0.060 |
Why?
|
Probability | 1 | 2003 | 160 | 0.060 |
Why?
|
Electroencephalography | 1 | 2003 | 73 | 0.060 |
Why?
|
Colon | 1 | 2003 | 52 | 0.060 |
Why?
|
Homeless Youth | 1 | 2003 | 1 | 0.060 |
Why?
|
Nutrition Disorders | 1 | 2003 | 12 | 0.050 |
Why?
|
Poverty | 1 | 2003 | 111 | 0.050 |
Why?
|
Optic Nerve Diseases | 1 | 2002 | 19 | 0.050 |
Why?
|
Asian Continental Ancestry Group | 1 | 2002 | 111 | 0.050 |
Why?
|
Biopsy, Needle | 1 | 2002 | 98 | 0.050 |
Why?
|
Lymph Node Excision | 1 | 2002 | 92 | 0.050 |
Why?
|
Drug Resistance, Microbial | 1 | 2001 | 14 | 0.050 |
Why?
|
Staining and Labeling | 1 | 2001 | 61 | 0.050 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2000 | 8 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2002 | 545 | 0.050 |
Why?
|
Reference Values | 2 | 2011 | 255 | 0.050 |
Why?
|
California | 1 | 2000 | 64 | 0.050 |
Why?
|
Hospitalization | 1 | 2003 | 465 | 0.050 |
Why?
|
Sex Chromosome Aberrations | 1 | 2000 | 4 | 0.040 |
Why?
|
X Chromosome | 1 | 2000 | 26 | 0.040 |
Why?
|
Acyl-CoA Dehydrogenase | 1 | 1999 | 2 | 0.040 |
Why?
|
Antibodies, Antinuclear | 1 | 2000 | 18 | 0.040 |
Why?
|
Acidosis | 1 | 1999 | 18 | 0.040 |
Why?
|
Nocardia asteroides | 1 | 1999 | 2 | 0.040 |
Why?
|
Mesna | 1 | 1999 | 3 | 0.040 |
Why?
|
Dactinomycin | 1 | 1999 | 12 | 0.040 |
Why?
|
Adenoviruses, Human | 1 | 2000 | 27 | 0.040 |
Why?
|
Ifosfamide | 1 | 1999 | 6 | 0.040 |
Why?
|
Antibodies, Helminth | 1 | 1999 | 1 | 0.040 |
Why?
|
Hepatic Encephalopathy | 1 | 1999 | 2 | 0.040 |
Why?
|
Etoposide | 1 | 1999 | 34 | 0.040 |
Why?
|
Nutritional Support | 1 | 1999 | 4 | 0.040 |
Why?
|
Aspergillus fumigatus | 1 | 1999 | 5 | 0.040 |
Why?
|
Polyradiculoneuropathy | 1 | 1999 | 1 | 0.040 |
Why?
|
Autoimmune Diseases | 1 | 2000 | 49 | 0.040 |
Why?
|
Aspergillosis | 1 | 1999 | 9 | 0.040 |
Why?
|
Carboplatin | 1 | 1999 | 48 | 0.040 |
Why?
|
Soft Tissue Infections | 1 | 1999 | 10 | 0.040 |
Why?
|
Wound Infection | 1 | 1999 | 12 | 0.040 |
Why?
|
Glomerulonephritis, Membranous | 1 | 1999 | 6 | 0.040 |
Why?
|
Graves Disease | 1 | 1999 | 6 | 0.040 |
Why?
|
Glasgow Coma Scale | 1 | 1999 | 27 | 0.040 |
Why?
|
Hypoglycemia | 1 | 1999 | 46 | 0.040 |
Why?
|
Intracranial Pressure | 1 | 1999 | 20 | 0.040 |
Why?
|
Nutrition Assessment | 1 | 1999 | 55 | 0.040 |
Why?
|
Soft Tissue Neoplasms | 1 | 1999 | 39 | 0.040 |
Why?
|
Bacteria | 1 | 2019 | 50 | 0.040 |
Why?
|
Doxorubicin | 1 | 1999 | 79 | 0.040 |
Why?
|
Antimalarials | 1 | 1999 | 6 | 0.040 |
Why?
|
Disease-Free Survival | 1 | 1999 | 320 | 0.040 |
Why?
|
Phosphates | 1 | 1998 | 25 | 0.040 |
Why?
|
Clostridium | 1 | 1998 | 4 | 0.040 |
Why?
|
Prolapse | 1 | 1998 | 5 | 0.040 |
Why?
|
Fecal Impaction | 1 | 1998 | 1 | 0.040 |
Why?
|
Colostomy | 1 | 1998 | 4 | 0.040 |
Why?
|
Anus Diseases | 1 | 1998 | 2 | 0.040 |
Why?
|
Erythrocyte Indices | 1 | 1998 | 4 | 0.040 |
Why?
|
Drug Evaluation | 1 | 1998 | 15 | 0.040 |
Why?
|
Fetal Hemoglobin | 1 | 1998 | 4 | 0.040 |
Why?
|
Metronidazole | 1 | 1998 | 15 | 0.040 |
Why?
|
Radiography, Thoracic | 1 | 1998 | 45 | 0.040 |
Why?
|
Hydroxychloroquine | 1 | 1998 | 11 | 0.040 |
Why?
|
Subclavian Artery | 1 | 1998 | 6 | 0.040 |
Why?
|
Fecal Incontinence | 1 | 1998 | 23 | 0.040 |
Why?
|
Diagnostic Errors | 1 | 1998 | 46 | 0.040 |
Why?
|
Enteral Nutrition | 1 | 1998 | 30 | 0.040 |
Why?
|
Emergency Treatment | 1 | 1998 | 43 | 0.040 |
Why?
|
Neck | 1 | 1998 | 26 | 0.040 |
Why?
|
Anti-Infective Agents | 1 | 1998 | 43 | 0.040 |
Why?
|
Ascorbic Acid | 1 | 1998 | 23 | 0.040 |
Why?
|
Angiography | 1 | 1998 | 80 | 0.040 |
Why?
|
Clostridium botulinum | 1 | 1997 | 3 | 0.040 |
Why?
|
Age of Onset | 1 | 1998 | 100 | 0.040 |
Why?
|
Cephalosporins | 1 | 1997 | 8 | 0.040 |
Why?
|
Phenotype | 1 | 2000 | 656 | 0.040 |
Why?
|
Carotid Arteries | 1 | 1998 | 100 | 0.040 |
Why?
|
Botulism | 1 | 1997 | 9 | 0.040 |
Why?
|
Gastroscopy | 1 | 1997 | 8 | 0.040 |
Why?
|
Fever of Unknown Origin | 1 | 1997 | 10 | 0.040 |
Why?
|
Recurrence | 1 | 1998 | 266 | 0.040 |
Why?
|
Kuru | 1 | 1997 | 1 | 0.040 |
Why?
|
Gerstmann-Straussler-Scheinker Disease | 1 | 1997 | 1 | 0.040 |
Why?
|
Encephalopathy, Bovine Spongiform | 1 | 1997 | 2 | 0.040 |
Why?
|
Creutzfeldt-Jakob Syndrome | 1 | 1997 | 6 | 0.040 |
Why?
|
Mediterranean Region | 1 | 1996 | 1 | 0.040 |
Why?
|
Middle East | 1 | 1996 | 5 | 0.040 |
Why?
|
Accidents, Traffic | 1 | 1999 | 195 | 0.040 |
Why?
|
Cattle | 1 | 1997 | 101 | 0.040 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 1996 | 49 | 0.030 |
Why?
|
Sociology | 1 | 2015 | 2 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 1998 | 502 | 0.030 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2014 | 6 | 0.030 |
Why?
|
Peer Group | 1 | 2014 | 44 | 0.030 |
Why?
|
Placebos | 1 | 2014 | 66 | 0.030 |
Why?
|
Neisseria meningitidis | 1 | 2013 | 1 | 0.030 |
Why?
|
Antidepressive Agents | 1 | 2014 | 77 | 0.030 |
Why?
|
Continental Population Groups | 1 | 2015 | 239 | 0.030 |
Why?
|
Blood | 1 | 2013 | 10 | 0.030 |
Why?
|
Feces | 1 | 2013 | 36 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2012 | 19 | 0.030 |
Why?
|
Drug Eruptions | 1 | 2012 | 9 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2011 | 29 | 0.030 |
Why?
|
HIV Seronegativity | 1 | 2011 | 5 | 0.020 |
Why?
|
Abortion, Spontaneous | 1 | 2011 | 12 | 0.020 |
Why?
|
Blotting, Western | 1 | 2012 | 305 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2013 | 786 | 0.020 |
Why?
|
Viremia | 1 | 2010 | 5 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2011 | 91 | 0.020 |
Why?
|
DNA Primers | 1 | 2010 | 90 | 0.020 |
Why?
|
Phylogeny | 1 | 2010 | 56 | 0.020 |
Why?
|
Virus Replication | 1 | 2010 | 52 | 0.020 |
Why?
|
Critical Illness | 1 | 2011 | 89 | 0.020 |
Why?
|
Base Sequence | 1 | 2010 | 257 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2010 | 359 | 0.020 |
Why?
|
Survival Analysis | 1 | 2011 | 491 | 0.020 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2008 | 9 | 0.020 |
Why?
|
Herpesvirus 4, Human | 1 | 2008 | 9 | 0.020 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2008 | 10 | 0.020 |
Why?
|
Cytomegalovirus | 1 | 2008 | 28 | 0.020 |
Why?
|
Specimen Handling | 1 | 2008 | 35 | 0.020 |
Why?
|
Cell Count | 1 | 2007 | 52 | 0.020 |
Why?
|
Sodium | 1 | 2007 | 39 | 0.020 |
Why?
|
Potassium | 1 | 2007 | 40 | 0.020 |
Why?
|
Leukocytes | 1 | 2007 | 60 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2007 | 190 | 0.020 |
Why?
|
Perineum | 1 | 2006 | 18 | 0.020 |
Why?
|
Infant Nutrition Disorders | 1 | 2004 | 1 | 0.010 |
Why?
|
Infant Food | 1 | 2004 | 3 | 0.010 |
Why?
|
Gases | 1 | 2003 | 3 | 0.010 |
Why?
|
Educational Status | 1 | 2004 | 177 | 0.010 |
Why?
|
Feeding Behavior | 1 | 2004 | 162 | 0.010 |
Why?
|
Decision Making | 1 | 2004 | 205 | 0.010 |
Why?
|
Immunocompetence | 1 | 1999 | 12 | 0.010 |
Why?
|
Musculoskeletal Diseases | 1 | 2000 | 38 | 0.010 |
Why?
|
Kidney Glomerulus | 1 | 1999 | 31 | 0.010 |
Why?
|